17336-14-0

Upstream product

• 96-97-9 5-nitrosalicylic acid 
• 108-24-7 acetic anhydride 

Downstream Products

• 96-97-9 5-nitrosalicylic acid 
• 64-19-7 acetic acid 
• 543-24-8 N-acetylglycine 
• 97-69-8 (S)-acetamidoalanine 
• 997-55-7 N-Acetyl-L-aspartic acid 
• 1188-37-0 N-acetyl-(S)-glutamic acid 
• 2497-02-1 N-acetyl-L-histidine 
• 1375074-73-9 4-imino-7-nitro-3-phenyl-2-thioxo-1,2,3,4-tetrahydro-5H-chromeno[2,3-d]pyrimidine-5-one 
• 19479-87-9 (O-carboxymethyl)hydroxylamine 
• 546-88-3 acetylhydroxamic acid 
• 1245209-66-8 5-nitro-2-acetoxybenzoyl azide 
• 53855-63-3 2-acetyloxy-5-nitrobenzoyl chloride 
• 115978-96-6 (Z)-1,3,3-trimethyl-2-(2-hydroxy-5-nitrophenacylidene)indoline 
• 115978-95-5 (E)-1,3,3-trimethyl-2-(2-hydroxy-5-nitrophenacylidene)indoline 

Relevant academic research and scientific papers

N-BENZYLANILINE DERIVATIVE AND USES THEREOF

Disclosed are an N-benzylaniline derivative and uses thereof. The derivative is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has an action of protecting against cerebral ischemia/reperfusion injury and an

N-BENZYLANILINE DERIVATIVE AND USES THEREOF

A N-benzylaniline derivative and uses thereof. The derivative is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound protects against cerebral ischemia/reperfusion injury and has analgesic action for chronic pat

4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

The structure-based design of potent and selective urokinase-type plasminogen activator (uPA) inhibitors with 4-aminoarylamidine or 4-aminoarylguanidine S1 binding groups, is described.

Multiple behaviors in the cleavage of aryl alkanoates by αand β-cyclodextrins. Processes involving two molecules of cyclodextrin

The kinetics of ester cleavage of 4-carboxy-2- nitrophenyl alkanoates (1) (C2-C8) and of 2- carboxy-4-nitrophenyl alkanoates (2) (C2, C4,C6, C8) in an aqueous phosphate buffer (pH 11.7) containing α- orβ-cyclodextrin (α- or β-CD) show various types of behavior. Depending on the ester, its acyl chain, and the CD, the kinetics show acceleration (with or without saturation), retardation, acceleration and retardation, retardation and acceleration, or two kinds of acceleration. However, this diversity can be rationalized with simple reaction schemes. Short-chain esters mainly react conventionally through binary CD-ester complexes. For longer chains, some ester/CD combinations exhibit nonproductive 2:1 (CD:ester) binding, whereas other combinations show a cleavage process involving two CD molecules. The latter is most likely due to the attack of a CD (anion) on the 1:1 CD-ester complex or to reaction within a weak 2:1 complex. Modes of transition-state binding are probed using the pseudoequilibrium constants (KTS) introduced in earlier work (Carbohydr. Res. 1989, 192, 181).

Protease inhibitors

This invention relates to methods of preventing or reducing the degradation of elastin and other proteins and thereby preventing or retarding the disease states caused by said degradation by administering compounds, some of which are novel, of the formula: STR1 or their pharmacologically acceptable salts.